News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

MAKING 2020 THE YEAR OF PROFESSIONAL DEVELOPMENT

For makers, manufacturers, project managers, managers and data analysts, making time for training and upskilling employees and leaders could be a key competitive advantage in 2020

Releasing its industry-honed training and certificate calendar, Oregon Bioscience Association has scheduled more than 20 classes in the first half of 2020. The professional development-track sessions and a combination certificate program highlight process control and improvement, regulatory and compliance updates, Lean Six Sigma methods, ISO 13485:2016 standardization, high performance teamwork, communications, data analysis, […]

December 4, 2019 |

Skanska works with Oregon Health Authority as OHA provides 8,000 opioid overdose reversal safety kits to businesses around Oregon

Oregon Bio member Skanska in Oregon and Southwest Washington has teamed up with SafeBuild Alliance and with many local construction companies, the Multnomah County’s health division and the Oregon Health Authority (OHA) to roll out “Reverse Overdose Oregon.” OHA’s campaign launched November 18 at Skanska’s offices as part of a statewide business-to-business effort to address the opioid epidemic through direct, comprehensive interventions.

The Oregon Health Authority (OHA) announced its new project to support Oregon employers in adopting opioid overdose response programs […]

December 2, 2019 |

SPOTLIGHT ON OREGON BIO WINNERS

On Oct. 29, industry expert judges and attendees picked the four winners of the Oregon Bioscience Association’s 2019 Research Fast Pitch and Company Pitch Fest competition. Entrants competed for more than $15,000 worth of cash and prizes, designed to further their study and commercialization potential. The presentations and voting happened at the Oregon Bio 2019: Innovating and Scaling for our Region’s Growth conference.

The winner was Sparrow Pharmaceuticals and its President, David Katz, Ph.D. Dr. Katz presented Sparrow’s […]

Innovative Cell Therapy Research Boosted by State Funds

November 13, 2019 – https://around.uoregon.edu/content/innovative-cell-therapy-research-boosted-state-funds

An innovative new research project from UO’s Robert Guldberg has captured the attention of Oregon’s economic development agency Business Oregon and the UO’s Office of the Vice President for Research and Innovation.

Guldberg’s $1.2 million project, which zeroes in on one of the central challenges of the fast-growing cell therapy industry, is the first to tap into the University Innovation Research Fund. The new state fund is designed to support research at Oregon universities that drives innovation […]

November 14, 2019 |

Voice of Industry: Lisa Hale, CEO of Grace Bio-Labs, Part 2

After catching up recently with Lisa Hale, CEO of Grace Bio-Labs (see Part 1 of the conversation here),  Oregon Bio asked her a few more questions. Grace Bio-Labs is headquartered in Bend, Oregon. Having launched three decades ago, the company is now a globally recognized developer and manufacturer of tools for life science research, working to understand how protein and single-cell interactions are relevant in cancer detection.

As a voice of industry, we wanted to hear more about Grace […]

November 12, 2019 |

OREGON BIO NAMES WINNING BIOSCIENCE COMPANIES AND LIFE SCIENCE RESEARCHERS

Two emerging bio companies and two rising-star researchers were chosen at Oregon Bio 2019: Innovating and Scaling for our Region’s Growth conference in Portland. Company Pitch Fest winner notes, “[We] appreciate the recognition this award provides for the potential impact of our efforts to deliver next generation steroid products with a substantially improved safety”

Industry expert judges and attendees picked the four winners of the Oregon Bioscience Association’s 2019 Research Fast Pitch and Company Pitch Fest competition this week. Entrants […]

October 31, 2019 |

OHSU earns Deals of Distinction™ Award for the Industry-University-Government Interface Sector

LES to Honor 15th Annual Deals of Distinction™ Award Winners at its Phoenix Annual Meeting, October 21-23

LES Members to Be Recognized for Outstanding Achievements in the Field of Licensing Business Deals at LES 2019 Annual Meeting in Phoenix, October 21

RESTON, VA. – Sept. 30, 2019 — The Licensing Executives Society (U.S.A and Canada), Inc. (LES) today announced the recipients of its Deals of Distinction™ Awards in four industry sectors. The annual program, now in its fifteenth year, recognizes […]

October 14, 2019 |

Policy Points: Oregon Bio advocates for patient-centered care, repealing the medical device excise tax, and inviting members to review FDA draft guidance for the Safer Technologies Program

Oregon Bio’s public advocacy work on behalf of its members has turned its attention to federal congressional actions. OR Bio members are invited to reach out to their Member of Congress* to learn more about these important, current issues: 

Could patient-centered care be outlawed by House Resolution 3?  HR3 includes the Lower Drug Costs Now Act 2019, which aims to create reference pricing structures, introduces price control mechanisms from foreign countries, and imposes extreme penalties on U.S. innovation, researchers and drug developers. These penalties are said to include an […]

Voice of Industry: Lisa Hale, CEO of Grace Bio-Labs, Part 1

Oregon Bio recently caught up with Lisa Hale, CEO of Grace Bio-Labs, headquartered in Bend, Oregon. Started three decades ago, the company has grown as a globally recognized developer and manufacturer of tools for life science research, working to understand how protein and single-cell interactions are relevant in cancer detection. 

As a voice of industry, we wanted to hear Grace Bio-Labs perspective: 

OR Bio: How does Grace Bio-Labs fit into Oregon’s biotech and life science ecosystem? The region? 

LH:  Typically when you hear the term “biotech” you think of the Bay Area, Seattle, […]

WHAT 8 OREGON BIOSCIENCE COMPANIES AND 8 LIFE SCIENCE RESEARCHERS HAVE IN COMMON

Emerging bio companies and researchers are selected to present, showcasing leading thought in bioscience innovation at Oregon Bio 2019: Innovating and Scaling for our Region’s Growth – the conference created for investors, start-up entrepreneurs, executives, researchers and policymakers, happening Oct. 29 in Portland.  #OregonBio2019

FOR IMMEDIATE RELEASE – October 9, 2019

CONTACT: Dianne Danowski Smith, (503) 201-7019, @OregonBio

(Portland, Ore.)  – The Oregon Bioscience Association announced the eight regional bioscience companies, representing the device, diagnostic, digital health and therapeutics sectors, selected […]

October 9, 2019 |

For the first time in many years, the government reported that spending on health care last year grew more slowly than the economy overall. [...]

Welcome to Thursday's Overnight Health Care. House Democrats will vote next week on Speaker Nancy Pelosi's signature drug pricing proposal, youth tobacco use is growing, Planned Parenthood i [...]

The U.S. spent more than $1 trillion on hospitals in 2018, the largest percentage of all health spending, according to a new government analysis of health spending released Thursday.The study from the [...]

Eli Lilly is revamping its cancer research unit, combining the oncology team at Lilly Research Laboratories with Loxo Oncology, the biotech it picked up for $8 billion in January--and putting a trio o [...]

Gilead and HHS have had a busy year in PrEP, including a patent lawsuit, but now they're starting a program to provide HIV prevention meds to those who can benefit for free. Under the program, HH [...]

Sage Therapeutics' key phase 3 trial in major depressive disorder has missed its primary endpoint. The failure of SAGE-217 to beat placebo wiped more than 50% off Sage's share price as inves [...]

Add facial cuts, bruises and fractures to the risks from cellphones and carelessly using them. That’s according to a study published Thursday that found a spike in U.S. emergency room treatment for th [...]

Immunomedics has had a long and troubled road in the past few years that has included losing much of its C-suite after an FDA rejection, not to mention the strange failure of a $2 billion deal with Se [...]